Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 110 clinical trials
The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis

This study investigated the effect of mycophenolate mofetil and cyclosphosphamide on lymphocyte subsets in patients with proliferative lupus nephritis. Patients with biopsy-proven Class III/IV

nephritis
azathioprine
cyclophosphamide
prednisolone
proteinuria
  • 20 views
  • 22 Jan, 2021
  • 1 location
Mesenchymal Stromal Cells (MSC s) in Renal Lupus

Phase II Clinical Trial to Assess the dose-response and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells (MSCs) in Severe Renal Systemic Lupus Erythematosus (SLE).

nephropathy
cyclophosphamide
mycophenolate
kidney biopsy
urinary sediment
  • 17 views
  • 26 Jan, 2021
  • 3 locations
Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency

arthritis and lupus nephritis, it's serum concentration will not be affected by renal function, and it also has antiviral effect. There are two randomized controlled trials and a retrospective study

immunoglobulins
nephropathy
immunosuppression
kidney biopsy
primary iga nephropathy
  • 0 views
  • 24 Jan, 2021
  • 1 location
CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid

Glucocorticoids (GC) use has increased survival of patients with systemic lupus erythematosus (SLE), particularly in cases of nephritis and a more significant improvement to 80% with the

glomerulonephritis
corticosteroids
nephritis
immunosuppressive agents
cyclophosphamide
  • 17 views
  • 17 Apr, 2021
  • 6 locations
Atrasentan in Patients With Proteinuric Glomerular Diseases

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

  • 0 views
  • 15 May, 2021
  • 14 locations
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy Focal Segmental Glomerulosclerosis and Treatment-Resistant Minimal Change Disease

This is a phase 2a study evaluating the safety and tolerability of multiple ascending doses of GFB-887 in patients with diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD).

glycosylated hemoglobin
nephropathy
focal segmental glomerulosclerosis
minimal change disease
glomerulosclerosis
  • 69 views
  • 06 May, 2021
  • 48 locations
  • 0 views
  • 16 Apr, 2021
  • 1 location
A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy

To determine the nephroprotective potential of treatment with sparsentan in patients newly-diagnosed with immunoglobulin A nephropathy (IgAN) (ie, incident patients) who have not received prior angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Belimumab With Rituximab for Primary Membranous Nephropathy

treat MN. Treatment with a combination of belimumab and rituximab has not been studied in individuals with MN, but it is currently being tested in other autoimmune diseases, including lupus nephritis

glomerular filtration rate
nephropathy
monoclonal antibodies
remission
arthritis
  • 206 views
  • 28 Jan, 2021
  • 10 locations
Kidney Fibrosis and MRI

patients with active lupus nephritis.

renal fibrosis
nephritis
kidney transplant
renal failure
kidney biopsy
  • 3 views
  • 05 Feb, 2021
  • 1 location